Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct 25;12(10):e11150.
doi: 10.7759/cureus.11150.

Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases

Ouissam Al Jarroudi  1 , Ayhan Ulusakarya  2 , Wathek Almohamad  2 , Said Afqir  1 , Jean-Francois Morere  2
Affiliations
Case Reports

Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases

Ouissam Al Jarroudi et al. Cureus. .

Abstract

The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. To determine the efficacy and safety of immunotherapy in liver transplant recipients, we report three cases of recurrent metastatic HCC after liver transplantation who were treated with nivolumab as off-label salvage therapy.

Keywords: hepatocellular carcinoma; liver transplantation; pd-1 inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Hepatocellular carcinoma. El Serag HB. N Engl J Med. 2011;365:1118–1127. - PubMed
    1. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. Finkelmeier F, Czauderna C, Perkhofer L, et al. https://link.springer.com/article/10.1007%2Fs00432-018-2780-8. J Cancer Res Clin Oncol. 2019;145:253–259. - PMC - PubMed
    1. Reccurent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Transpl Int. 2013;26:109–118. - PubMed
    1. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. Yoo HY, Patt CH, Geschwind JF, Trojan PJ. J Clin Oncol. 2003;21:4329–4335. - PubMed
    1. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm. Au KP, Chok KSH. World J Gastroenterol. 2018;24:5081–5094. - PMC - PubMed

Publication types

LinkOut - more resources